Hpv vaccine: India Launches Nationwide Campaign to Combat Cervical Cancer

Reaction from the field

The recent launch of a nationwide HPV vaccination program in India is expected to significantly reduce the burden of cervical cancer, which is the second-most prevalent form of cancer among women in the country. Cervical cancer is primarily caused by the human papillomavirus (HPV), and the vaccine can prevent nearly 90% of these cases. This initiative, which began on February 28, 2026, aims to vaccinate 14-year-old girls across the nation, providing them with a crucial tool in the fight against this disease.

The vaccination program is notable for its accessibility, as the HPV vaccine is administered free of cost at government health facilities. Vaccination is voluntary and requires parental consent, ensuring that families have a choice in their healthcare decisions. Dr. Chandini, a health expert, emphasized the importance of the vaccine, stating, “The HPV vaccine is safe and can prevent nearly 90 percent of cervical cancer, which is the second most common cancer among women in India.” This statement underscores the critical role the vaccine will play in protecting young girls from a disease that has a significant impact on women’s health.

India currently has three approved HPV vaccines: Cervarix®, Gardasil®, and Gardasil-9®. Additionally, Cervavac®, developed by the Serum Institute of India, was approved by the Drug Controller General of India in July 2022. The ongoing vaccination campaign will utilize the single-dose Gardasil-4 vaccine, which is considered cost-effective at a threshold of 30% of GDP per capita. This cost-effectiveness is crucial for a country where healthcare resources can be limited.

With India accounting for over 65% of the regional burden of cervical cancer, the vaccination program is a vital step towards reducing these statistics. The campaign is expected to last for 90 days, during which health officials will work to ensure that as many eligible girls as possible receive the vaccine. The initiative is supported by various organizations, including the World Health Organization and Gavi, which aim to strengthen preventive healthcare measures in the country.

The introduction of HPV vaccines in India dates back to 2008, with state governments in Sikkim and Punjab launching their own vaccination programs in 2016. However, the current nationwide effort marks a significant escalation in the commitment to combat cervical cancer through vaccination. The program’s success will depend on public awareness and participation, as well as the effective distribution of vaccines across diverse regions.

As the vaccination campaign progresses, health officials will monitor its impact on cervical cancer rates and overall public health. The hope is that this initiative will not only protect young girls from cervical cancer but also pave the way for a broader understanding of preventive healthcare in India. The ongoing nationwide HPV vaccination program will contribute to reducing the burden of cervical cancer and strengthening preventive healthcare in India.

Details remain unconfirmed regarding the long-term effects of this vaccination campaign on cervical cancer rates, but the initial response from the public and health professionals has been positive. The success of this program could serve as a model for other countries facing similar health challenges, highlighting the importance of vaccination in public health strategies.